Literature DB >> 23279158

Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism.

N Scherz1, M Méan, A Limacher, M Righini, K Jaeger, H-J Beer, B Frauchiger, J Osterwalder, N Kucher, C M Matter, M Banyai, A Angelillo-Scherrer, B Lämmle, M Husmann, M Egloff, M Aschwanden, H Bounameaux, J Cornuz, N Rodondi, D Aujesky.   

Abstract

BACKGROUND: The Outpatient Bleeding Risk Index (OBRI) and the Kuijer, RIETE and Kearon scores are clinical prognostic scores for bleeding in patients receiving oral anticoagulants for venous thromboembolism (VTE). We prospectively compared the performance of these scores in elderly patients with VTE.
METHODS: In a prospective multicenter Swiss cohort study, we studied 663 patients aged ≥ 65 years with acute VTE. The outcome was a first major bleeding at 90 days. We classified patients into three categories of bleeding risk (low, intermediate and high) according to each score and dichotomized patients as high vs. low or intermediate risk. We calculated the area under the receiver-operating characteristic (ROC) curve, positive predictive values and likelihood ratios for each score.
RESULTS: Overall, 28 out of 663 patients (4.2%, 95% confidence interval [CI] 2.8-6.0%) had a first major bleeding within 90 days. According to different scores, the rate of major bleeding varied from 1.9% to 2.1% in low-risk, from 4.2% to 5.0% in intermediate-risk and from 3.1% to 6.6% in high-risk patients. The discriminative power of the scores was poor to moderate, with areas under the ROC curve ranging from 0.49 to 0.60 (P = 0.21). The positive predictive values and positive likelihood ratios were low and varied from 3.1% to 6.6% and from 0.72 to 1.59, respectively.
CONCLUSION: In elderly patients with VTE, existing bleeding risk scores do not have sufficient accuracy and power to discriminate between patients with VTE who are at a high risk of short-term major bleeding and those who are not.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23279158     DOI: 10.1111/jth.12111

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  15 in total

Review 1.  Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Authors:  Geoffrey D Barnes; Yogendra Kanthi; James B Froehlich
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

Review 2.  Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.

Authors:  Davide Imberti; Fulvio Pomero; Daniela Mastroiacovo
Journal:  Blood Transfus       Date:  2019-04-30       Impact factor: 3.443

3.  Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment.

Authors:  Yoann Gaboreau; Nora Zenatti; Céline Vermorel; Patrick Imbert; Jean-Luc Bosson; Gilles Pernod
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

4.  Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism.

Authors:  F A Klok; C Niemann; C Dellas; G Hasenfuß; S Konstantinides; M Lankeit
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

Review 5.  Assessing bleeding risk in patients taking anticoagulants.

Authors:  Marwa Shoeb; Margaret C Fang
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

6.  Hospitalizations of adults ≥60 years of age with venous thromboembolism.

Authors:  Hussain R Yusuf; Nimia Reyes; Qing C Zhang; Ekwutosi M Okoroh; Azfar-E-Alam Siddiqi; James Tsai
Journal:  Clin Appl Thromb Hemost       Date:  2013-06-27       Impact factor: 2.389

7.  Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.

Authors:  Amir Kuperman; Raquel López-Reyes; Lopez-Saez Juan Bosco; Alicia Lorenzo; Bascuñana José; Dominique Farge Bancel; María Alfonso; Marina Lumbierres; Galia Stemer; Manuel Monreal Bosch; Andrei Braester
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

8.  Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry.

Authors:  Chiara Piovella; Fabio Dalla Valle; Javier Trujillo-Santos; Raffaele Pesavento; Leonor López; Llorenç Font; Reina Valle; Dolores Nauffal; Manuel Monreal; Paolo Prandoni
Journal:  Intern Emerg Med       Date:  2014-05-17       Impact factor: 3.397

9.  Clinical characteristics, time course, and outcomes of major bleeding according to bleeding site in patients with venous thromboembolism.

Authors:  Behnood Bikdeli; Fares Moustafa; José Antonio Nieto; Alfred I Lee; Nuria Ruíz-Giménez; Alicia Lorenzo; Sebastian Schellong; Silvia Soler; Salvador Ortíz; Mª Del Valle Morales; Marijan Bosevski; Olga Gavín; Gregory Y H Lip; Manuel Monreal
Journal:  Thromb Res       Date:  2022-01-14       Impact factor: 3.944

10.  The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.

Authors:  Judith Kooiman; Nadja van Hagen; Antonio Iglesias Del Sol; Erwin V Planken; Gregory Y H Lip; Felix J M van der Meer; Suzanne C Cannegieter; Frederikus A Klok; Menno V Huisman
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.